ReviewDiscover oncology2026
Non-coding RNA-mediated mechanisms underlying tamoxifen resistance in breast cancer.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tamoxifen remains a cornerstone therapy for estrogen receptor-positive (ER⁺) breast cancer; however, the emergence of drug resistance significantly limits its therapeutic success. Growing evidence has revealed that non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), act as pivotal regulators of the molecular networks driving tamoxifen resistance. These “silent regulators” modulate multiple signaling pathways, including PI3K/AKT, MAPK, and estrogen receptor signaling, through mechanisms such as post-transcriptional regulation, epigenetic modification, and competitive endogenous RNA (ceRNA) interactions. Dysregulated ncRNAs can alter drug efflux, apoptosis, cell cycle progression, and epithelial–mesenchymal transition (EMT), contributing to reduced tamoxifen sensitivity and tumor recurrence. Our knowledge of BC resistance to tamoxifen will be aided by the new molecular insights into the mechanistic understanding of resistance to endocrine treatment as a whole that come from the growing functions of ncRNAs as miRNA sponges, transcriptional scaffolds, and ceRNAs, among others. The biosynthesis and molecular properties of ncRNAs, their involvement in tamoxifen resistance, and their potential use as therapeutic targets or diagnostic biomarkers are the main topics of this thorough analysis. In order to perhaps serve as a foundation for upcoming RNA-based therapies aimed at overcoming endocrine resistance in ER⁺ BC, we would also consolidate the current body of knowledge.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.